title: Belinostat: clinical applications in solid tumors and lymphoma.
abstract: BACKGROUND
  Histone deacetylase (HDAC) inhibitors have recently emerged as a novel and active class of anticancer agents. Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma.
  
  
  METHODS
  A literature search of pre-clinical and clinical studies of belinostat was performed. The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. The parallel development of appropriate biomarker analysis is also discussed.
  
  
  CONCLUSIONS
  Belinostat has demonstrated significant clinical activity in T-cell lymphomas. Although its activity as a single agent in solid tumors has been less compelling, the emerging results from combination trials are promising. However, the basis for the activity of belinostat, like that of other HDAC inhibitors, remains to be truly defined and the identification of predictive and prognostic biomarkers of activity should be established to further progress the development of this compound.
authors: Drug Development Unit, Division of Clinical Sciences, The Institute of Cancer Research/The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK. rhoda.molife@icr.ac.uk
authors: L Rhoda
authors: LR
authors: Molife
authors: Johann S
authors: JS
authors: de Bono
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D013449:Sulfonamides
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat